Immunotherapy Makes a Difference in Relapsed Hodgkin LymphomaTargeted OncologyBriones, chief of the Hematology Service, Hospital de la Santa Creu i Sant Pau in Barcelona, Spain, discussed the rationale for treating patients with Hodgkin lymphoma with … Continue reading
Immunotherapy Makes a Difference in Relapsed Hodgkin LymphomaTargeted OncologyBriones, chief of the Hematology Service, Hospital de la Santa Creu i Sant Pau in Barcelona, Spain, discussed the rationale for treating patients with Hodgkin lymphoma with … Continue reading
O’Dwyer’s PR NewsAgency Debuts Gene Therapy DivisionO’Dwyer’s PR NewsHealthcare communications shop The Ruth Group has launched a new specialized practice dedicated solely to the gene therapy and gene editing sector. The newly assembled unit, which is … Continue reading
Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid LeukemiaTargeted OncologyChimeric antigen receptor (CAR) T-cell therapy is a novel form of cellular immunotherapy in which autologous T cells are genetically modified to express CARs found on tu… Continue reading
Targeted OncologyChimeric Antigen Receptor T-Cell Therapy in Acute Myeloid LeukemiaTargeted OncologyChimeric antigen receptor (CAR) T-cell therapy is a novel form of cellular immunotherapy in which autologous T cells are genetically modified to express… Continue reading
FDA Orphan Drug Designation Granted to Hemophilia Gene Therapy; Clinical Studies to Begin SoonRare Disease Report (blog)The U.S. Food and Drug Administration (FDA) has granted Shire with orphan drug designation for its gene therapy candidate SHP654, in… Continue reading
Winchester Herald ChronicleVanderbilt-Ingram Cancer Center Patients Treated with New FDA-Approved CAR T TherapyNewswise (press release)Newswise — Vanderbilt-Ingram Cancer Center (VICC) has been selected as one of the few authorized treatment centers in… Continue reading
|
Incyte to Develop MacroGenics’ Cancer Immunotherapy MGA012 in Up-to-$900M+ Collab
Genetic Engineering & Biotechnology News Incyte will partner with MacroGenics to develop its Phase I cancer immunotherapy candidate MGA012, a monoclonal antibody designed to inhibit programmed cell death protein 1 (PD-1), through a collaboration that could generate up to $900 million-plus for … |